Stock SILVAPHL SILVA PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Silva Pharmaceuticals Limited

Equities

SILVAPHL

BD0493SPL001

Pharmaceuticals

End-of-day quote Dhaka S.E.
Other stock markets
 03:30:00 24/06/2024 am IST 		5-day change 1st Jan Change
15.5 BDT -2.52% Intraday chart for Silva Pharmaceuticals Limited -4.32% -28.24%
29/04 Silva Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
29/01 Silva Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023
Capitalization 1 2,990 2,498 2,689 3,290 2,948
Enterprise Value (EV) 1 2,696 2,304 2,461 3,127 2,829
P/E ratio 20.1 x 21 x 22.4 x 32.2 x 89.1 x
Yield 2.61% 2.73% 2.54% 1.24% 0.46%
Capitalization / Revenue 4.08 x 3.27 x 3.36 x 4.22 x 4.11 x
EV / Revenue 3.68 x 3.02 x 3.08 x 4.02 x 3.95 x
EV / EBITDA 13.5 x 11 x 11.9 x 17.9 x 26.4 x
EV / FCF -44.7 x -39.2 x 46.2 x -64.6 x -100 x
FCF Yield -2.24% -2.55% 2.16% -1.55% -1%
Price to Book 1.4 x 1.14 x 1.18 x 1.41 x 1.26 x
Nbr of stocks (in thousands) 1,36,500 1,36,500 1,36,500 1,36,500 1,36,500
Reference price 2 21.90 18.30 19.70 24.10 21.60
Announcement Date 04/11/19 27/10/20 07/12/21 11/12/22 07/12/23
1BDT in Million2BDT
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 685.2 732.5 763.3 799.2 778.7 716.9
EBITDA 1 192.7 200.2 208.6 207.4 174.3 107.3
EBIT 1 140.7 142.8 139.9 142.1 111.8 44.78
Operating Margin 20.53% 19.5% 18.33% 17.78% 14.35% 6.25%
Earnings before Tax (EBT) 1 143.9 157.3 159.1 151.3 116.7 50.36
Net income 1 92.99 143.3 118.9 119.9 102.3 33.08
Net margin 13.57% 19.57% 15.58% 15% 13.13% 4.61%
EPS 2 0.8857 1.091 0.8714 0.8780 0.7491 0.2423
Free Cash Flow 1 76.04 -60.27 -58.77 53.24 -48.45 -28.2
FCF margin 11.1% -8.23% -7.7% 6.66% -6.22% -3.93%
FCF Conversion (EBITDA) 39.46% - - 25.67% - -
FCF Conversion (Net income) 81.77% - - 44.42% - -
Dividend per Share - 0.5714 0.5000 0.5000 0.3000 0.1000
Announcement Date 08/08/18 04/11/19 27/10/20 07/12/21 11/12/22 07/12/23
1BDT in Million2BDT
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 36.3 294 194 228 162 120
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 76 -60.3 -58.8 53.2 -48.4 -28.2
ROE (net income / shareholders' equity) 5.54% 7.46% 5.49% 5.36% 4.45% 1.42%
ROA (Net income/ Total Assets) 4.46% 4.15% 3.68% 3.62% 2.8% 1.11%
Assets 1 2,086 3,455 3,236 3,309 3,654 2,983
Book Value Per Share 2 16.30 15.60 16.10 16.60 17.00 17.10
Cash Flow per Share 2 0.4800 0.3100 0.2700 0.4300 0.2700 0.2100
Capex 1 169 205 172 77.2 178 86.8
Capex / Sales 24.64% 28.03% 22.5% 9.66% 22.81% 12.11%
Announcement Date 08/08/18 04/11/19 27/10/20 07/12/21 11/12/22 07/12/23
1BDT in Million2BDT
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
SILVA PHARMACEUTICALS LIMITED Stock Silva Pharmaceuticals Limited
-28.24% 17.53M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.19% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+45.91% 654B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.09% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+21.92% 337B
ASTRAZENECA PLC Stock AstraZeneca PLC
+19.72% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+3.72% 229B
NOVARTIS AG Stock Novartis AG
+14.21% 219B
AMGEN INC. Stock Amgen Inc.
+10.86% 171B
PFIZER, INC. Stock Pfizer, Inc.
-2.78% 159B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. SILVAPHL Stock
  4. Financials Silva Pharmaceuticals Limited